Nalinee Sripaung has completed her PhD from Tokyo Medical and Dental University, Japan. She is the Assistant Director of Bureau of Occupational and Environmental Diseases, Department of Disease Control, Ministry of Public Health, Thailand. She has experience working with the Thai National Chemicals Management Strategy for prevention and control of occupational and environmental diseases. She has published more than 30 papers in chemicals dissemination and reputed journals and has been serving as an Editorial Board Member of reputed journal in Thailand.
According to the type of metabolites in blood and urine acting as the biomarker, the concentration of biomarker acts as the indicator for health risk assessment. The health risk management, concerning with chemical toxicity, faces the problem of how to use the concentration of biomarker to be the suitable indicator for health risk assessment. Presently, there is no safety value adjustment of health risk assessment for people’s health in community. Therefore, the field of prevention and control of occupational and environmental diseases has to use the safety value of biomarker concentration for worker’s health to be the safety value for people’s health indicator in community for health risk assessment resulted from chemical pollution. The study of using the safety value of worker’s health to identify people’s health in community in case of health surveillance of chemical incidents was proceeded during the year 2015-2016. It was found that biomarkers concentrations of VOCs (Volatile Organic Solvents) of worker’s health were higher than the actual baseline chemicals exposure of People’s health in community. The result from the adjustment of the risk group of people in community by worker’s health safety value indicated the lower amount of people than the actual amount risk group. Thus, the baseline concentration of biomarker should be further studied to be the health surveillance value for people’s health risk assessment caused by chemicals toxicity.
Anastasia O. Sosnovtseva is a PhD-student at the Pirogov Russian National Research Medical University. Her research interests focus on oncolytic virotherapy.
Oncolytic virotherapy is a new promising approach to treatment of various oncological diseases. At present Sendai Virus (SeV) is being actively investigated as a promising oncolytic drug. A number of studies have shown that recombinant and UV inactivated SeV is capable of effective elimination of tumor cells while sparing normal cells. SeV eradicates tumor cells mostly via induction of apoptosis, autophagy and necroptosis and, also, by induction of antitumor immunity. \r\nIn this study we have demonstrated that primary lines derived from adenocarcinoma of prostate exhibit a differential sensitivity to SeV. It’s necessary to uncover genetic markers of interaction between malignant cells and viruses to enable a personalized approach to treatment and increase effectiveness of virotherapy. Quantitative PCR was used to estimate levels of expression of genes encoding RIG-1 like and Toll like receptors (TLR). It was demonstrated that levels of expression of TLR3 and TLR7 correlated with the degree of sensitivity of tumor cells from prostate gland to Sendai virus in a statistically significant way. Cell lines with the least expression of TLR3 and TLR7 exhibit the highest degree of sensitivity to that virus. A more detailed investigation of the mechanism of action of that viral strain will allow to uncover additional markers that would enable prediction of sensitivity of tumors from a particular patient to SeV and effectiveness of the oncolytic drug in the therapeutic regimen used with an utmost accuracy.\r\nAcknowledgements: our research was supported by Russian Ministry of Education grant RFMEFI60714X0067.\r\n\r\n